Kymera Therapeutics (KYMR) Short-term Investments (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Short-term Investments data on file, last reported at $506.8 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $506.8 million, up 35.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $506.8 million (up 35.81% YoY), and the FY2025 annual result was $491.3 million, up 33.32% from the prior year.
• Short-term Investments rose to $506.8 million in Q1 2026 per KYMR's latest filing, from $491.3 million in the prior quarter.
• Over five years, Short-term Investments peaked at $506.8 million in Q1 2026 and troughed at $264.9 million in Q4 2023.
• A 5-year average of $376.0 million and a median of $368.5 million in 2024 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2024 and 2025: Short-term Investments soared 58.7% in 2024, then declined 25.48% in 2025.
• A 5-year view of Short-term Investments shows it stood at $338.8 million in 2022, then retreated by 21.8% to $264.9 million in 2023, then jumped by 39.1% to $368.5 million in 2024, then surged by 33.32% to $491.3 million in 2025, then increased by 3.17% to $506.8 million in 2026.
• Business Quant data shows KYMR's Short-term Investments at $506.8 million in Q1 2026, $491.3 million in Q4 2025, and $392.7 million in Q3 2025.